Virologic and Immunologic Responses in Treatment-Naive Patients to Ritonavir-Boosted Atazanavir or Efavirenz With a Common Backbone

REFERENCES

• Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012;308(4):387–402.
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adoles-cents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed July 24,2013.
   Google Scholar
• Daar ES, Tierney C, Fischl MA, et al. Atazanavir plus rito-navir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011;154(7):445–456.
   PubMed Web of Science ®Google Scholar
• Elzi L, Erb S, Furrer H, et al. Choice of initial combina-tion antiretroviral therapy in individuals with HIV infec-tion: Determinants and outcomes. Arch Intern Med. 2012;172(17)1 313–1321.
   Google Scholar
• Taniguchi T, Grubb JR, Nurutdinova D, et al. Efavirenz outperforms boosted atazanavir among treatment-naive HIV-1-infected persons in routine clinical care. J Int Assoc Provid AIDS Care. 2013;12(2):138–141.
   PubMedGoogle Scholar
• Puls RL, Srasuebkul P, Petoumenos K, et al. Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: Week 48 data from the Altair study. Clin Infect Dis. 2010;51(7):855–864.
   PubMed Web of Science ®Google Scholar
• Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: The importance of rigorous methods. BMJ. 1996;313(7048):36–39.
   PubMed Web of Science ®Google Scholar
• Schoeni-Affolter F, Ledergerber B, Rickenbach M, et al. Cohort profile: The Swiss HIV Cohort study. Int J Epide-miol. 2010;39(5)1179–1189.
   Google Scholar
• Glass TR, De Geest S, Hirschel B, et al. Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients. Antivir Ther. 2008;13(1):77–85.
   PubMed Web of Science ®Google Scholar
• Gallant JE. Making sense of blips. J Infect Dis. 2007;196(12)1 729–1731.
   Web of Science ®Google Scholar
• Young J, Bucher HC, Guenthard HF, et al. Virological and immunological responses to efavirenz or boosted lopina-vir as first-line therapy for patients with HIV. Antivir Ther. 2009;14(6):771–779.
   PubMed Web of Science ®Google Scholar
• Hernan MA, Brumback BA, Robins JM. Estimating the causal effect of zidovudine on CD4 count with a mar-ginal structural model for repeated measures. Stat Med. 2002;21(12):1689–1709.
   PubMed Web of Science ®Google Scholar
• Cole SR, Hernan MA, Margolick JB, Cohen MH, Robins JM. Marginal structural models for estimating the effect of highly active antiretroviral therapy initiation on CD4 cell count. Am J Epidemiol. 2005;162(5):471–478.
   PubMed Web of Science ®Google Scholar
• Carlin JB, Wolfe R, Coffey C, Patton GC. Analysis of binary outcomes in longitudinal studies using weighted estimat-ing equations and discrete-time survival methods: Preva-lence and incidence of smoking in an adolescent cohort. Stat Med. 1999;18(19):2655–2679.
   PubMed Web of Science ®Google Scholar
• Hernan MA, Brumback B, Robins JM. Marginal struc-tural models to estimate the causal effect of zidovu-dine on the survival of HIV-positive men. Epidemiology. 2000;11(5):561–570.
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equa-tion to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612.
   PubMed Web of Science ®Google Scholar
• Cole SR, Hernan MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008;168(6):656–664.
   PubMed Web of Science ®Google Scholar
• Hauck WW, Anderson S, Marcus SM. Should we adjust for covariates in nonlinear regression analyses of randomized trials? Control Clin Trials. 1998;19(3):249–256.
   PubMedGoogle Scholar
• Greenland S, Schwartzbaum JA, Finkle WD. Problems due to small samples and sparse data in conditional logistic regression analysis. Am J Epidemiol. 2000;151(5):531–539.
   PubMed Web of Science ®Google Scholar
• Lipsitz SR, Ibrahim J, Molenberghs G. Using a Box-Cox transformation in the analysis of longitudinal data with incomplete responses. J R Stat Soc Ser. C Appl Stat. 2000;49(3):287–296.
   Web of Science ®Google Scholar
• Hogg RS, Yip B, Chan KJ, et al. Rates of disease progres-sion by baseline CD4 cell count and viral load after initiat-ing triple-drug therapy. JAMA. 2001;286(20):2568–2577.
   PubMed Web of Science ®Google Scholar
• Egger M, May M, Chene G, et al. Prognosis of HIV-1-in-fected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet. 2002;360(9327)119–129.
   Web of Science ®Google Scholar
• Phillips AN, Lundgren JD. The CD4 lymphocyte count and risk of clinical progression. Curr Opin HIV AIDS. 2006;1(1):43–49.
   PubMed Web of Science ®Google Scholar
• Young J, Psichogiou M, Meyer L, et al. CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combi-nation antiretroviral therapy with a suppressed viral load: A longitudinal cohort study from COHERE. PLoS Med. 2012;9(3):e1001194.
   PubMed Web of Science ®Google Scholar
• Maggiolo F, Ravasio L, Ripamonti D, et al. Similar adher-ence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibi-tors. Clin Infect Dis. 2005;40(1):158–163.
   PubMed Web of Science ®Google Scholar
• Andersson LM, Vesterbacka J, Blaxhult A, et al. Lopinavir/ ritonavir, atazanavir/ritonavir, and efavirenz in antiretrovi-ral-naive HIV-1-infected individuals over 144 weeks: An open-label randomized controlled trial. Scand J Infect Dis. 2013;45(7):543–551.
   PubMed Web of Science ®Google Scholar
• Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combina-tion with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr. 2004;36(5)1 011–1019.
   Web of Science ®Google Scholar
• Honda M, Ishisaka M, Ishizuka N, Kimura S, Oka S. Open-label randomized multicenter selection study of once daily antiretroviral treatment regimen comparing ritonavir-boosted atazanavir to efavirenz with fixed-dose abacavir and lamivudine. Intern Med. 2011;50(7):699–705.
   PubMed Web of Science ®Google Scholar
• Lima VD, Nosyk B, Wood E, et al. Assessing the effectiveness of antiretroviral regimens in cohort studies involving HIV-positive injection drug users. AIDS. 2012;26(12):1491–1500.
   PubMed Web of Science ®Google Scholar
• McComsey GA, Kitch D, Sax PE, et al. Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s. Clin Infect Dis. 2011;53(2)1 85–196.
   Web of Science ®Google Scholar
• Young J, Schafer J, Fux CA, et al. Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. AIDS. 2012;26(5): 567–575.
   PubMed Web of Science ®Google Scholar
• Gupta S, Kitch D, Tierney C, et al. Long-term changes in renal parameters in ART-naive subjects randomized to abacavir/lamivudine or tenofovir/emtricitabine with ata-zanavir/ritonavir or efavirenz: ACTG A5224s, a sub-study of A5202. Presented at: 20th Conference on Retroviruses and Opportunistic Infections; March 3–6, 2013; Atlanta, GA. Abstract 811.
   Google Scholar
• Gotti D, Cesana BM, Albini L, et al. Increase in standard cholesterol and large HDL particle subclasses in antiret-roviral-naive patients prescribed efavirenz compared to atazanavir/ritonavir. HIV Clin Trials. 201213(5):245–255.
   Google Scholar
• Lubomirov R, Colombo S, di Lulio J, et al. Association of pharmacogenetic markers with premature discontinua-tion of first-line anti-HIV therapy: An observational cohort study. J Infect Dis. 2011;203(2):246–257.
   PubMed Web of Science ®Google Scholar